$128.93
0.73% today
Nasdaq, Aug 12, 10:04 pm CET
ISIN
US09062X1037
Symbol
BIIB

Biogen Stock price

$128.00
-6.21 4.63% 1M
-11.39 8.17% 6M
-24.92 16.30% YTD
-73.04 36.33% 1Y
-90.22 41.34% 3Y
-161.94 55.85% 5Y
-162.01 55.86% 10Y
+89.56 233.01% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-2.67 2.04%
ISIN
US09062X1037
Symbol
BIIB
Industry

Key metrics

Basic
Market capitalization
$18.8b
Enterprise Value
$22.3b
Net debt
$3.5b
Cash
$2.8b
Shares outstanding
146.6m
Valuation (TTM | estimate)
P/E
12.3 | 8.4
P/S
1.9 | 2.0
EV/Sales
2.2 | 2.4
EV/FCF
12.1
P/B
1.1
Financial Health
Equity Ratio
59.6%
Return on Equity
9.8%
ROCE
10.9%
ROIC
9.8%
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$10.0b | $9.4b
EBITDA
$3.2b | $3.4b
EBIT
$2.7b | $2.9b
Net Income
$1.5b | $2.2b
Free Cash Flow
$1.8b
Growth (TTM | estimate)
Revenue
3.4% | -2.4%
EBITDA
26.8% | 10.7%
EBIT
23.3% | 11.0%
Net Income
32.1% | 37.1%
Free Cash Flow
25.8%
Margin (TTM | estimate)
Gross
75.4%
EBITDA
32.0% | 35.6%
EBIT
27.4%
Net
15.3% | 23.7%
Free Cash Flow
18.5%
More
EPS
$10.4
FCF per Share
$12.6
Short interest
3.4%
Employees
8k
Rev per Employee
$1.3m
Show more

Create a Free Account to create an Biogen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Biogen Stock Analysis

Unlock Scores for Free

Analyst Opinions

43 Analysts have issued a Biogen forecast:

20x Buy
47%
22x Hold
51%
1x Sell
2%

Analyst Opinions

43 Analysts have issued a Biogen forecast:

Buy
47%
Hold
51%
Sell
2%

Financial data from Biogen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
9,997 9,997
3% 3%
100%
- Direct Costs 2,457 2,457
4% 4%
25%
7,541 7,541
3% 3%
75%
- Selling and Administrative Expenses 2,411 2,411
5% 5%
24%
- Research and Development Expense 1,885 1,885
17% 17%
19%
3,194 3,194
27% 27%
32%
- Depreciation and Amortization 461 461
52% 52%
5%
EBIT (Operating Income) EBIT 2,734 2,734
23% 23%
27%
Net Profit 1,531 1,531
32% 32%
15%

In millions USD.

Don't miss a Thing! We will send you all news about Biogen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biogen Stock News

Neutral
GlobeNewsWire
one day ago
– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period –
Neutral
Business Wire
one day ago
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced that the first patient has been dosed in the global Phase 3 EMPEROR study of zorevunersen for the treatment of Dravet syndrome. Zorevun...
Positive
Seeking Alpha
10 days ago
Biogen beat Q2 2025 revenue and EPS estimates, but core MS and SPINRAZA franchises continue to erode, offset only partially by new products. Launches like ZURZUVAE and LEQEMBI show promise, yet their impact is limited by niche markets and slow adoption, tempering growth expectations. Cost discipline and improved profitability are positives, but the company's long-term growth remains challenged ...
More Biogen News

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Head office United States
CEO Christopher Viehbacher
Employees 7,605
Founded 1978
Website www.biogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today